Article
A proteogenomic portrait of lung squamous cell carcinoma.
Cell - 5 Aug 2021
Satpathy Shankha, Krug Karsten, Jean Beltran Pierre M, Savage Sara R, Petralia Francesca, Kumar-Sinha Chandan, Dou Yongchao, Reva Boris, Kane M Harry, Avanessian Shayan C, Vasaikar Suhas V, Krek Azra, Lei Jonathan T, Jaehnig Eric J, Omelchenko Tatiana, Geffen Yifat, Bergstrom Erik J, Stathias Vasileios, Christianson Karen E, Heiman David I, Cieslik Marcin P, Cao Song, Song Xiaoyu, Ji Jiayi, Liu Wenke, Li Kai, Wen Bo, Li Yize, Gümüş Zeynep H, Selvan Myvizhi Esai, Soundararajan Rama, Visal Tanvi H, Raso Maria G, Parra Edwin Roger, Babur Özgün, Vats Pankaj, Anand Shankara, Schraink Tobias, Cornwell MacIntosh, Rodrigues Fernanda Martins, Zhu Houxiang, Mo Chia-Kuei, Zhang Yuping, da Veiga Leprevost Felipe, Huang Chen, Chinnaiyan Arul M, Wyczalkowski Matthew A, Omenn Gilbert S, Newton Chelsea J, Schurer Stephan, Ruggles Kelly V, Fenyö David, Jewell Scott D, Thiagarajan Mathangi, Mesri Mehdi, Rodriguez Henry, Mani Sendurai A, Udeshi Namrata D, Getz Gad, Suh James, Li Qing Kay, Hostetter Galen, Paik Paul K, Dhanasekaran Saravana M, Govindan Ramaswamy, Ding Li, Robles Ana I, Clauser Karl R, Nesvizhskii Alexey I, Wang Pei, Carr Steven A, Zhang Bing, Mani D R, Gillette Michael A
Abstract excerpt
Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We identify NSD3 as an alternative driver in FGFR1-amplified tumors and low-p63 tumors overexpressing the therapeutic target survivin. SOX2 is considered undruggable,...
Read the complete abstract on PubMed